Losartan, an Angiotensin-II Receptor Antagonist, Retards the Progression of Advanced Renal Insufficiency

DOI Web Site 被引用文献1件 参考文献34件
  • Osawa Hiroshi
    The Second Department of Internal Medicine, Hirosaki University School of Medicine The Department of General Medicine, Hirosaki University School of Medicine
  • Nakamura Norio
    The Second Department of Internal Medicine, Hirosaki University School of Medicine
  • Shirato Kenichi
    The Second Department of Internal Medicine, Hirosaki University School of Medicine
  • Nakamura Masayuki
    The Second Department of Internal Medicine, Hirosaki University School of Medicine
  • Shimada Michiko
    The Second Department of Internal Medicine, Hirosaki University School of Medicine
  • Kumasaka Ryuichirou
    The Second Department of Internal Medicine, Hirosaki University School of Medicine
  • Murakami Reiichi
    The Second Department of Internal Medicine, Hirosaki University School of Medicine
  • Fujita Takeshi
    The Second Department of Internal Medicine, Hirosaki University School of Medicine
  • Yamabe Hideaki
    The Second Department of Internal Medicine, Hirosaki University School of Medicine
  • Okumura Ken
    The Second Department of Internal Medicine, Hirosaki University School of Medicine

この論文をさがす

抄録

Chronic renal disease with elevated level of serum creatinine (Cr) often progresses to end-stage renal disease. Although blockade of the renin-angiotensin system has been shown to slow the progression of chronic renal disease, it remains uncertain whether one could expect such a renoprotective effect even when the treatment is initiated late in the course of renal disease. The purpose of the present study was to examine the effect of losartan, an angiotensin-II receptor antagonist, on the progression of advanced renal insufficiency. We retrospectively analyzed eight hypertensive patients, whose baseline Cr levels exceeded 2.0 mg/dl (2.2-5.5); the subjects included 6 non-diabetic glomerular diseases, 1 diabetic nephropathy and 1 polycystic kidney disease. Losartan was given at the dosage of 25-50 mg/day. Changes in mean blood pressure (MBP) and serum levels of Cr, potassium (K) and uric acid were evaluated after treatment for 24 weeks. Slopes of reciprocal of serum Cr plotted against time (1/sCr slope), which indicate the rate of renal function loss before and after the treatment period, were compared. There was a significant reduction of 1/sCr slope after losartan (−0.004 ± 0.002 dl/mg/week before and −0.001 ± 0.002 dl/mg/week after the treatment, p < 0.05). MBP and serum levels of Cr, K and uric acid were not changed significantly by losartan treatment. However, improvement of 1/sCr slope was correlated to the degree of MBP changes. Based on the available data from 4 patients, proteinuria was decreased in 3 patients. These results suggest that losartan may retard the progression of advanced renal insufficiency.

収録刊行物

被引用文献 (1)*注記

もっと見る

参考文献 (34)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ